flu vaccine from England

Managers would boost vaccine production 37 percent at its aging British factory to grab a bigger slice of the U.S. market, growing amid fears of vaccine shortages.
...
Chiron is now focused on fixing problems at the Liverpool plant, bought last year for nearly $1 billion despite its history of contamination problems, so it can deliver flu vaccine to the USA next year.
...
It is unclear what steps, such as beefing up staff or equipment, Chiron took to boost production at the former PowderJect Pharmaceuticals plant. Executives, in conference calls with securities analysts since buying the plant, spoke often of raising productivity, comparing the Liverpool plant’s performance with Chiron factories in Italy and Germany.

Four years ago, British health authorities told Celltech, which then owned the factory, to withdraw an oral polio vaccine because of concerns about contamination at the plant, according to British news accounts. Celltech’s production problems were coupled with a collapse in sales. It sold the plant to PowderJect in September 2000.